Just about the most beneath-investigated “driving forces” involved with trastuzumab resistance is PTEN. Nagata et al. (2004) reported that the lack of PTEN was observed in 36% of HER2-optimistic primary breast tumor specimens from people with stage IV disease. Also, they also confirmed t